NCT00044447已完成3 期
A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 170
- 试验地点
- 2
- 主要终点
- Change in HbA1C from baseline to Week 26.
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have given their signed informed consent.
- •Males or females between 18 and 80 years old. Female patients must be surgically sterile, post-menopausal, or using an accepted method of birth control (i.e., oral contraceptives, intrauterine device, Norplant® system, Depo Provera®, or a spermicide and condom). Female patients of childbearing potential must have a negative serum pregnancy test and be advised not to become pregnant during the study.
- •At least 1 year history of NIDDM and performing home blood glucose monitoring.
- •Patients must have BMI of > 26 to < 42 kg/m2 at baseline (week 0).
- •Patients must have HbA1C > 7.5% but < 9.5% at screen (week -4).
- •Patients must have evidence of insulin secretory capacity (fasting C-peptide concentration > or equal to 0.27 nmol/l during the stabilization period).
- •Patients must have FPG > 130 mg/dl but < 235 mg/dl prior to (within 48-72 hours) randomization at Visit 1 Week
- •Patients must be receiving as their current diabetic therapy stable doses of metformin (at dose of 1.0-2.5gm/day), or metformin extended release at a maximum dose of 2 gm/day and a half maximum to a maximum dose of thiazolidinedione for at least 3 months.
- •Patients must be able to understand and willing to adhere to and be compliant with the study protocol.
排除标准
- •Patients who require insulin therapy or are currently on other sulfonylureas.
- •Patients with a history of hypersensitivity to sulfonylureas.
- •Patients with past history of severe hypoglycemia reaction on their current antidiabetic therapy requiring medical attention.
- •Patients with a history of acute metabolic complications such as hyperosmolar coma or ketonuria.
- •Patients with clinically significant abnormal baseline laboratory values (hematology, blood chemistry or urinalysis) which define a disease or condition, which in the opinion of the investigator may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate and complete the study. Should there be a laboratory value which, upon initial screening, is substantially outside the normal range, the test should be repeated.
- •Patients who had an increase in their thiazolidinedione medication within 2 months of entering the study (Visit 0).
- •Patients who had an increase in the metformin medication within 1 month of entering the study (Visit 0).
- •Patients whose body weight has changed more than 2% for patients < 250 pounds or 3% for patients >= 250 pounds, during the 4 week stabilization period when compared to the weight at the screening visit 0 (week - 4).
- •Patients with acute infections.
- •Patients who have received any drug (i.e. a chemotherapy agent) with a well-defined potential for toxicity to a major organ system during the three months prior to the study.
- •Patients with clinically significant renal or hepatic disease (i.e. ALT > 2.5 x upper limit of normal) or gastrointestinal disorders that may interfere with absorption of the study drugs.
- •Patients who are allergic to sulfonamides and excipients.
- •Patients with any history of alcohol or drug abuse.
- •Pregnant or lactating females will be excluded.
- •Patients with a history of psychosis, emotional or intellectual problems that could impair the ability of the patient to participate in the study or to complete the study.
- •Patients who have participated in any investigational study within 30 days prior to Visit 0.
结局指标
主要结局
Change in HbA1C from baseline to Week 26.
次要结局
- Incidence of hypoglycemia.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis BChronic Hepatitis BNCT04182321Fu-Sheng Wang60
已完成
4 期
Metformin in Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT01247870St George's, University of London52
已完成
2 期
A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast CancerMetastatic Breast CancerNCT01310231Ozmosis Research Inc.40
已完成
4 期
Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00913367Handok Inc.110
Unknown
3 期
Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese PatientsObesityNCT00941382Laboratorios Silanes S.A. de C.V.60